102 related articles for article (PubMed ID: 2975951)
1. Survival, response and immune effects in a prospectively randomized study of dose strategy for alpha-N1 interferon.
Silver HK; Connors JM; Kong S; Karim KA; Spinelli JJ
Br J Cancer; 1988 Dec; 58(6):783-7. PubMed ID: 2975951
[TBL] [Abstract][Full Text] [Related]
2. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
Silver HK; Connors JM; Salinas FA
Cancer Treat Rep; 1985; 69(7-8):743-50. PubMed ID: 4016785
[TBL] [Abstract][Full Text] [Related]
3. Changes in immune function in patients receiving natural leukocyte interferon.
Maluish AE; Ortaldo JR; Sherwin SA; Oldham RK; Herberman RB
J Biol Response Mod; 1983; 2(5):418-27. PubMed ID: 6644346
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
6. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of low doses of alpha interferon in patients with breast cancer.
Laszlo J; Hood L; Cox E; Goodwin B
J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
[TBL] [Abstract][Full Text] [Related]
8. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
9. Extended phase I study of human beta-interferon in human cancer.
Abdi EA; Kamitomo VJ; McPherson TA; Konrad MW; Inoue M; Tan YH
Clin Invest Med; 1986; 9(1):33-40. PubMed ID: 3955919
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
11. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
Hersey P; Hasic E; MacDonald M; Edwards A; Spurling A; Coates AS; Milton GW; McCarthy WH
Br J Cancer; 1985 Jun; 51(6):815-26. PubMed ID: 3873953
[TBL] [Abstract][Full Text] [Related]
12. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients.
Silver HK; Connors JM; Karim KA; Kong S; Spinelli JJ; de Jong G; McLean DM; Salinas FA
J Biol Response Mod; 1983; 2(5):428-40. PubMed ID: 6644347
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.
Kirkwood JM; Harris JE; Vera R; Sandler S; Fischer DS; Khandekar J; Ernstoff MS; Gordon L; Lutes R; Bonomi P
Cancer Res; 1985 Feb; 45(2):863-71. PubMed ID: 3881175
[TBL] [Abstract][Full Text] [Related]
14. American cancer society Phase I trial of naturally produced beta-interferon.
Hawkins MJ; Krown SE; Borden EC; Krim M; Real FX; Edwards BS; Anderson SA; Cunningham-Rundles S; Oettgen HF
Cancer Res; 1984 Dec; 44(12 Pt 1):5934-8. PubMed ID: 6498851
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant interferon-alpha on immune function in cancer patients.
Maluish AE; Leavitt R; Sherwin SA; Oldham RK; Herberman RB
J Biol Response Mod; 1983; 2(5):470-81. PubMed ID: 6358423
[TBL] [Abstract][Full Text] [Related]
18. Low doses of interferon alpha result in more effective clinical natural killer cell activation.
Edwards BS; Merritt JA; Fuhlbrigge RC; Borden EC
J Clin Invest; 1985 Jun; 75(6):1908-13. PubMed ID: 4008643
[TBL] [Abstract][Full Text] [Related]
19. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
Koren HS; Brandt CP; Tso CY; Laszlo J
J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
[TBL] [Abstract][Full Text] [Related]
20. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
